The only form of PH that is potentially curable by surgery
Chronic Thromboembolic Pulmonary Hypertension, or CTEPH, is a rare, life-threatening medical condition whose most commonly reported symptoms include exercise intolerance, fatigue, and dyspnea. Subsequently, patients may report chest discomfort, syncope, hemoptysis, light-headedness, or peripheral leg edema.1
The symptoms experienced by CTEPH patients are similar to those of other more common diseases, like asthma and chronic obstructive pulmonary disease, and to those of other types of pulmonary hypertension (PH). In part because these symptoms are nonspecific, CTEPH is underdiagnosed, and it is often misdiagnosed as another disease.1,2
But CTEPH is unique among the five groups of pulmonary hypertension (PH) in that it is potentially curable only with pulmonary thromboendarterectomy* (PTE) surgery, which is the treatment of choice for patients who are surgical candidates.1
CTEPH.com is supported by Bayer HealthCare. Bayer is committed to advancing CTEPH best practices,3 including working to help educate the community that:
- All persons in whom PH is suspected should receive a ventilation/perfusion scan to screen for CTEPH.3
- All persons diagnosed with CTEPH should be assessed for potentially curative PTE surgery by an expert center.3
*Also called pulmonary endarterectomy or PEA.
Meet the experts on our editorial board who guide the overall direction of CTEPH.com.
Register now to receive timely updates and additional educational information. We will update this site every few months.
This site is dedicated to raising awareness about CTEPH and providing you with a resource to better understand: